Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Phase II Data Bolster vTv Therapeutics’ Glucokinase Activator Aspirations

Could Product Succeed Where SGLT2 Inhibitors Failed?

Executive Summary

The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.

You may also be interested in...



Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go

Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.

Sanofi And Lexicon Fall Out Over Zynquista, As French Group Exits Diabetes Pact

Lexicon labelled Sanofi’s unilateral decision to exit their alliance ‘invalid’ and said the French drugmaker was thus ‘in breach of contract’. Sanofi said its move was triggered by Phase III trial data studying the dual SGLT1 and SGLT2 inhibitor in type-2 diabetes. 

AstraZeneca’s Farxiga Fails To Get FDA OK As Insulin Supplement In Type 1 Diabetes

The UK pharma said the FDA had issued a complete response letter, declining its application for using Farxiga in the new T1D indication. Analysts suspect worries over diabetic ketoacidosis risk lie behind the rejection.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC141645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel